ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference

ALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in com

Realty Income (NYSE: O) says it began investing in data centers in late 2023 via a build-to-suit JV with Digital Realty, buying an 80% stake in an up to 48 MW facility. It also formed a hyperscale JV with Cloud Capital, targeting up to $1.4B investment for a 45% stake. Realty Income raised 2024 AFFO guidance to $4.44-$4.45/share and investment outlook to $10B.

Bloomberg reported the US Army plans to buy at least $400 million of AeroVironment counter-drone laser systems, citing a person familiar with the deal. The order would include dozens of LOCUST units that use AI to detect and track small to medium drones and then engage them with a high-energy laser. AeroVironment’s stock rose about 8% on Friday.

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

Diversified Energy (LSE:DEC, NYSE:DEC) said it will shift from acquisition-led growth to drilling its own wells, launching a one-rig operated development programme in Oklahoma in 2H, spending $35m to $50m. It expects drilling to materially affect 2027 production. Q2 adjusted EBITDA fell 14% to $240m; guidance calls for $960m-$1.01b adjusted earnings and ~$440m free cash flow.